# Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

> **NCT02658968** · PHASE1 · COMPLETED · sponsor: **Nordic Nanovector** · enrollment: 18 (actual)

## Conditions studied

- Relapsed, Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Betalutin

## Key facts

- **NCT ID:** NCT02658968
- **Lead sponsor:** Nordic Nanovector
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2021-06-04
- **Final completion:** 2021-07-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658968, "Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02658968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*